title: [Clinical case of management with intravitreal injection of Ranibizumab (Lucentis) on AMD predominant occult CNV: 6-month follow-up with FA, ICG-A, and OCT].
abstract: BACKGROUND
  Controlled clinical trial results of occult choroidal neovascularization (CNV) management in age-related macular degeneration (AMD) using intravitreal injections of Ranibizumab have shown significant improvement in vision for the treated group.
  
  
  METHODS
  The first clinical case of minimally classic CNV is reported here with the results at 6 months, not only with changes in visual acuity but also with complete imaging at each follow-up with fluorescein angiography, infracyanine angiography using the scanning laser ophthalmoscope (SLO) and with OCT examination. After the second injection, the patient experienced improvement in vision and complete regression of all symptoms to date (5 months after the first injection), showing very favorable progression during the entire follow-up.
  
  
  CONCLUSIONS
  This clinical case shows extremely favorable progression of the minimally classic lesion resulting from the first two injections of Lucentis. The situation is now stabilized in terms of function and morphology, as shown by the fluorescein and infracyanine SLO angiography and OCT examination.
authors.affiliation: Service d'Ophtalmologie, Centre hospitalier Intercommunal de Créteil, Créteil, France. gabriel.coscas@libertysurf.fr
authors.forename: G
authors.initials: G
authors.lastname: Coscas
authors.forename: F
authors.initials: F
authors.lastname: Coscas
authors.forename: G
authors.initials: G
authors.lastname: Soubrane
mesh_terms: D000368:Aged; D000792:Angiography / Q000379:methods; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green / Q000031:analogs & derivatives; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000069579:Ranibizumab; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C116320:Infracyanine green; D007208:Indocyanine Green; D000069579:Ranibizumab